SIG on Biotechnology

Chair: Dr Binodh DeSilva

Vice-Chairs: Dr Michael Ward (Australia) and Dr Hanns-Christian Mahler (Switzerland)


Overview

The FIP Biotechnology SIG is comprised of members from many diverse backgrounds in industry and academia and is dedicated to the discovery, development, and manufacturing of biotechnology-related pharmaceutical products and therapies through advances in science and technology.  The Biotechnology SIG will provide a dynamic international forum for the exchange of biotechnology-related knowledge among scientists of all disciplines to enhance their contributions to global health.  The Biotechnology SIG will offer timely biotechnology-related scientific programs, ongoing education for scientists both new and tenured to the field, as well as opportunities for networking and professional development.

The successful pharmaceutical advancement of biotechnology-related drugs requires cross-functional input from many diverse fields.  The SIG will examine both pharmaceutical progress as well as development challenges related to pharmaceutical Biotechnology in areas, including (but not limited to):

  • Bioanalytical Methods (e.g., Ligand Binding Assays)
  • Biomarkers  
  • Biosimilars / Biobetters
  • Biotherapeutics ADME   
  • Cell Therapy Products
  • Nucleic Acid Based Therapeutics 
  • Preformulation 
  • Protein Aggregation and Biological Consequences 
  • Protein Optimization
  • Scale-up
  • Therapeutic Protein Immunogenicity
  • Translational Medicine
  • Vaccines 

For more information on this SIG, please contact Dr DeSilva at Biotechnology@fip.org.